• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Phase 1/2a study of Lu-177-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    32877524.pdf
    Size:
    1.278Mb
    Format:
    PDF
    Description:
    From UNPAYWALL
    Download
    Authors
    Kolstad, A.
    Illidge, Timothy M
    Bolstad, N.
    Spetalen, S.
    Madsbu, U.
    Stokke, C.
    Blakkisrud, J.
    Londalen, A.
    O'Rourke, N.
    Beasley, M.
    Jurczak, W.
    Fagerli, U. M.
    Kascak, M.
    Bayne, M.
    Obr, A.
    Dahle, J.
    Rojkjaer, L.
    Pascal, V.
    Holte, H.
    Show allShow less
    Affiliation
    Department of Oncology, Oslo University Hospital, Radiumhospitalet, Oslo, Norway
    Issue Date
    2020
    
    Metadata
    Show full item record
    Abstract
    For patients with indolent non-Hodgkin lymphoma who fail initial anti-CD20-based immunochemotherapy or develop relapsed or refractory disease, there remains a significant unmet clinical need for new therapeutic approaches to improve outcomes and quality of life. 177Lu-lilotomab satetraxetan is a next-generation single-dose CD37-directed radioimmunotherapy (RIT) which was investigated in a phase 1/2a study in 74 patients with relapsed/refractory indolent non-Hodgkin B-cell lymphoma, including 57 patients with follicular lymphoma (FL). To improve targeting of 177Lu-lilotomab satetraxetan to tumor tissue and decrease hematologic toxicity, its administration was preceded by the anti-CD20 monoclonal antibody rituximab and the "cold" anti-CD37 antibody lilotomab. The most common adverse events (AEs) were reversible grade 3/4 neutropenia (31.6%) and thrombocytopenia (26.3%) with neutrophil and platelet count nadirs 5 to 7 weeks after RIT. The most frequent nonhematologic AE was grade 1/2 nausea (15.8%). With a single administration, the overall response rate was 61% (65% in patients with FL), including 30% complete responses. For FL with ≥2 prior therapies (n = 37), the overall response rate was 70%, including 32% complete responses. For patients with rituximab-refractory FL ≥2 prior therapies (n = 21), the overall response rate was 67%, and the complete response rate was 24%. The overall median duration of response was 13.6 months (32.0 months for patients with a complete response). 177Lu-lilotomab satetraxetan may provide a valuable alternative treatment approach in relapsed/refractory non-Hodgkin lymphoma, particularly in patients with comorbidities unsuitable for more intensive approaches. This trial was registered at www.clinicaltrials.gov as #NCT01796171.
    Citation
    Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C, et al. Phase 1/2a study of 177Lu-lilotomab satetraxetan in relapsed/refractory indolent non-Hodgkin lymphoma. Blood Adv. 2020;4(17):4091-101.
    Journal
    Blood Advances
    URI
    http://hdl.handle.net/10541/623335
    DOI
    10.1182/bloodadvances.2020002583
    PubMed ID
    32877524
    Additional Links
    https://dx.doi.org/10.1182/bloodadvances.2020002583
    Type
    Article
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1182/bloodadvances.2020002583
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Red Marrow-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with 177Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody-Radionuclide Conjugate.
    • Authors: Blakkisrud J, Løndalen A, Dahle J, Turner S, Holte H, Kolstad A, Stokke C
    • Issue date: 2017 Jan
    • Pre-dosing with lilotomab prior to therapy with <sup>177</sup>Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients.
    • Authors: Stokke C, Blakkisrud J, Løndalen A, Dahle J, Martinsen ACT, Holte H, Kolstad A
    • Issue date: 2018 Jul
    • Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate 177Lu-Lilotomab Satetraxetan.
    • Authors: Blakkisrud J, Løndalen A, Martinsen AC, Dahle J, Holtedahl JE, Bach-Gansmo T, Holte H, Kolstad A, Stokke C
    • Issue date: 2017 Jan
    • Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    • Authors: Plosker GL, Figgitt DP
    • Issue date: 2003
    • <sup>177</sup>Lu-Lilotomab Satetraxetan Has the Potential to Counteract Resistance to Rituximab in Non-Hodgkin Lymphoma.
    • Authors: Malenge MM, Patzke S, Ree AH, Stokke T, Ceuppens P, Middleton B, Dahle J, Repetto-Llamazares AHV
    • Issue date: 2020 Oct
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.